NCT06245551View on ClinicalTrials.gov

A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 22, 2023

Primary Completion Date

June 29, 2024

Study Completion Date

June 29, 2024

Conditions
Asthma, Exercise-Induced
Interventions
DRUG

Budesonide/albuterol metered-dose inhaler 160/180 μg

Budesonide/albuterol combination aerosol for inhalation, single dose (given as 2 actuations of 80/90 μg)

DRUG

Placebo metered-dose inhaler

Placebo aerosol for inhalation, single dose (given as 2 actuations)

Trial Locations (6)

105554

Research Site, Moscow

192071

Research Site, Saint Petersburg

410054

Research Site, Saratov

432009

Research Site, Ulyanovsk

440067

Research Site, Penza

614000

Research Site, Perm

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06245551 - A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma | Biotech Hunter | Biotech Hunter